Copyright
©The Author(s) 2022.
World J Clin Cases. May 6, 2022; 10(13): 3989-4019
Published online May 6, 2022. doi: 10.12998/wjcc.v10.i13.3989
Published online May 6, 2022. doi: 10.12998/wjcc.v10.i13.3989
Description | Gene markers | Solute carrier family 2 member 1 | Solute carrier family 2 member 2 | ||
cor | P value | cor | P value | ||
CD8+ T cell | |||||
CD8A | 0.24 | 3.10E-06 | -0.084 | 1.10E-01 | |
CD8B | 0.26 | 3.20E-07 | -0.13 | 1.40E-02 | |
T cell (general) | |||||
CD3D | 0.18 | 5.10E-04 | -0.23 | 1.10E-05 | |
CD3E | 0.15 | 4.00E-03 | -0.11 | 3.90E-02 | |
CD2 | 0.17 | 1.50E-03 | -0.12 | 2.60E-02 | |
B cell | |||||
CD19 | 0.22 | 1.60E-05 | -0.073 | 1.60E-01 | |
CD79A | 0.036 | 4.90E-01 | -0.59 | 2.60E-01 | |
Monocyte | |||||
CD86 | 0.39 | 1.50E-14 | -0.16 | 1.70E-03 | |
CD115 (CSF1R) | 0.36 | 1.40E-12 | -0.14 | 5.40E-03 | |
Tumor-associated macrophage | |||||
CCL2 | 0.16 | 2.30E-03 | -0.13 | 1.50E-02 | |
CD68 | 0.27 | 9.20E-08 | -0.14 | 6.50E-03 | |
IL10 | 0.32 | 2.50E-10 | -0.095 | 6.70E-02 | |
M1 macrophage | |||||
INOS (NOS2) | -0.031 | 5.50E-01 | 0.2 | 1.20E-04 | |
IRF5 | 0.14 | 7.40E-03 | 0.044 | 4.00E-01 | |
COX2 (PTGS2) | 0.16 | 1.50E-03 | -0.028 | 5.90E-01 | |
M2 macrophage | |||||
CD163 | 0.31 | 7.00E-10 | -0.13 | 1.40E-02 | |
VSIG4 | 0.36 | 1.10E-12 | -0.12 | 1.80E-02 | |
MS4A4A | 0.29 | 1.50E-08 | -0.11 | 2.80E-02 | |
CD66b (CEACAM8) | 0.074 | 1.60E-01 | -0.018 | 7.30E-01 | |
Neutrophil | |||||
CD11b (ITGAM) | 0.28 | 5.80E-08 | -0.074 | 1.60E-01 | |
CCR7 | 0.039 | 4.60E-01 | -0.028 | 5.90E-01 | |
Natural killer cell | |||||
KIR2DL1 | 0.087 | 9.40E-02 | -0.059 | 2.60E-01 | |
KIR2DL3 | 0.13 | 1.40E-02 | -0.05 | 3.40E-01 | |
KIR2DL4 | 0.18 | 7.10E-04 | -0.12 | 2.00E-02 | |
KIR3DL1 | 0.086 | 9.70E-02 | -0.058 | 2.70E-01 | |
KIR3DL2 | 0.069 | 1.90E-01 | -0.0081 | 8.80E-01 | |
KIR3DL3 | 0.08 | 1.30E-01 | -0.068 | 1.90E-01 | |
KIR2DS4 | 0.044 | 4.00E-01 | 0.02 | 7.10E-01 | |
Dendritic cell | |||||
HLA-DPB1 | 0.25 | 1.40E-06 | -0.16 | 2.20E-03 | |
HLA-DQB1 | 0.14 | 8.10E-03 | -0.19 | 2.60E-04 | |
HLA-DRA | 0.26 | 6.00E-07 | -0.15 | 5.00E-03 | |
HLA-DPA1 | 0.2 | 8.00E-05 | -0.12 | 2.30E-02 | |
BDCA-1 (CD1C) | 0.12 | 2.40E-02 | -0.044 | 4.00E-01 | |
BDCA-4 (NRP1) | 0.23 | 6.80E-06 | -0.037 | 4.80E-01 | |
CD11c (ITGAX) | 0.24 | 2.00E-06 | -0.13 | 1.40E-02 | |
Th1 | |||||
T-bet (TBX21) | 0.088 | 9.00E-02 | -0.058 | 2.70E-01 | |
STAT4 | 0.0027 | 9.60E-01 | -0.041 | 4.40E-01 | |
STAT1 | 0.13 | 1.10E-02 | 0.017 | 7.50E-01 | |
IFN-γ (IFNG) | 0.19 | 3.30E-04 | -0.1 | 4.70E-02 | |
TNF-α (TNF) | 0.12 | 2.00E-02 | -0.1 | 5.40E-02 | |
Th2 | |||||
GATA3 | 0.31 | 2.10E-09 | -0.13 | 1.20E-02 | |
STAT6 | 0.15 | 4.80E-03 | 0.19 | 2.40E-04 | |
STAT5A | 0.2 | 8.20E-05 | -0.07 | 1.80E-01 | |
IL13 | -0.025 | 6.30E-01 | -0.01 | 8.40E-01 | |
Tfh | |||||
BCL6 | 0.1 | 4.70E-02 | 0.24 | 2.70E-06 | |
IL21 | 0.072 | 1.70E-01 | -0.044 | 3.90E-01 | |
Th17 | |||||
IL17A | -0.022 | 6.70E-01 | 0.071 | 1.80E-01 | |
T cell regulatory | |||||
FOXP3 | -0.036 | 4.90E-01 | 0.17 | 1.40E-03 | |
CCR8 | 0.16 | 1.90E-03 | -0.082 | 1.20E-01 | |
STAT5B | 0.073 | 1.60E-01 | 0.43 | 0.00E+00 | |
TGFβ (TGFB1) | 0.24 | 2.10E-06 | -0.25 | 1.40E-06 | |
T cell exhaustion | |||||
PD-1 (PDCD1) | 0.08 | 1.20E-01 | -0.12 | 2.00E-02 | |
CTLA4 | 0.17 | 1.10E-03 | -0.18 | 7.20E-04 | |
LAG3 | 0.23 | 7.60E-06 | -0.19 | 3.30E-04 | |
TIM-3 (HAVCR2) | 0.22 | 1.30E-05 | -0.17 | 1.30E-03 | |
GZMB | 0.17 | 8.10E-04 | -0.16 | 2.20E-03 |
- Citation: Peng Q, Hao LY, Guo YL, Zhang ZQ, Ji JM, Xue Y, Liu YW, Lu JL, Li CG, Shi XL. Solute carrier family 2 members 1 and 2 as prognostic biomarkers in hepatocellular carcinoma associated with immune infiltration. World J Clin Cases 2022; 10(13): 3989-4019
- URL: https://www.wjgnet.com/2307-8960/full/v10/i13/3989.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i13.3989